A Phase Ib/II Study of PDR001 Plus Imatinib for Metastatic or Unresectable GIST With Prior Failure of Imatinib, Sunitinib and Regorafenib
Phase of Trial: Phase I/II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary) ; Spartalizumab (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 08 May 2019 Status changed from not yet recruiting to recruiting.
- 18 Oct 2018 Planned initiation date changed from 30 Sep 2018 to 30 Dec 2018.
- 06 Aug 2018 New trial record